Conference Coverage

Cannabis for pain linked to slight risk for arrhythmia


 

FROM ESC CONGRESS 2022

Cancer, musculoskeletal, and neurologic pain

For this analysis, the researchers identified 1.8 million patients in Denmark who were diagnosed with chronic pain between 2018 and 2021.

Of those, around 5,000 patients had claimed at least one prescription of medicinal cannabis (dronabinol 29%, cannabinoids 46%, or cannabidiol 25%).

The patients had a median age of 60 years, and 63% were women.

The cannabis users had been prescribed this therapy for musculoskeletal (35%), cancer (18%), neurological (14%), or other (33%) pain, Dr. Nouhravesh said.

The researchers and Dr. Olshansky have no relevant financial disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

COVID-19 has brought more complex, longer office visits
MDedge Hematology and Oncology
PRAGUE-17: LAA closure holds up against DOACs out to 4 years
MDedge Hematology and Oncology
Exercise reduces arm and shoulder problems after breast cancer surgery
MDedge Hematology and Oncology
What does a pig-to-human heart transplant mean for medicine?
MDedge Hematology and Oncology
CVS Caremark formulary change freezes out apixaban
MDedge Hematology and Oncology
Seniors face higher risk of other medical conditions after COVID-19
MDedge Hematology and Oncology
Cardiac arrest survival lower in COVID-19 inpatients
MDedge Hematology and Oncology
SCAI issues guidelines for PFO management, makes case for expansion
MDedge Hematology and Oncology
Heed cardiac risk of BTKis for CLL
MDedge Hematology and Oncology
Low-dose edoxaban curbs stroke risk in elderly with AF, despite frailty
MDedge Hematology and Oncology